Table 2 Comparison of the prediction value for EGFR-TKI therapy response in NSCLC patients using different methods (EGFR genotype and different labeling parameters of HX103-based FACS).a–d
Patient (No.) | EGFR mutations | First-line treatmenta | Therapy responseb | EGFR(+)HX103(+) (%)c | EGFR(+) (%)d | HX103(+) (%)e |
|---|---|---|---|---|---|---|
1 | 19del | Afatinib | PR | +(47.7) | + (73.8) | + (48.0) |
2 | 19del | Afatinib | PR | +(46.4) | + (58.2) | + (53.5) |
3 | L858R | Afatinib | SD | – (26.2) | + (64.5) | – (30.4) |
4 | L858R | Dacomitinib | PR | +(38.0) | + (48.3) | + (49.5) |
5 | 19del | Gefitinib | CR | +(54.7) | + (69.2) | + (61.9) |
6 | L858R | Dacomitinib | PR | +(42.6) | + (59.3) | + (48.6) |
7 | L858R | Gefitinib | PR | +(34.2) | – (35.2) | + (51.5) |
8 | 19del | Dacomitinib | PD | – (4.84) | – (11.2) | – (13.7) |
9 | L858R | Icotinib | NE | +(50.9) | + (49.8) | + (92.6) |
10 | 19del | Icotinib | CR | +(41.6) | + (48.7) | + (51.0) |
11 | L858R | Icotinib | SD | – (2.07) | – (0.83) | – (11.8) |
12 | L858R | Erlotinib | NE | +(30.8) | – (29.8) | + (76.0) |
13 | 19del | Gefitinib | PR | +(55.7) | + (53.9) | + (77.5) |
14 | 19del | Gefitinib | PR | +(30.8) | + (58.9) | + (45.5) |
15 | L858R | Afatinib | SD | – (4.81) | – (10.0) | – (12.1) |
16 | – | Other | SD | – (2.61) | – (9.10) | – (5.01) |
17 | – | Other | PR | – (13.7) | + (39.4) | – (21.9) |
18 | – | Other | PR | – (4.44) | – (16.9) | – (11.0) |
19 | – | Other | SD | – (3.27) | – (12.5) | – (7.41) |
20 | – | Other | SD | – (0.60) | – (10.9) | – (3.16) |
21 | – | None | NE | – (−0.3) | – (21.3) | – (−1.8) |
22 | – | Other | NE | – (1.35) | – (−3.51) | – (3.59) |
23 | – | Other | NE | – (4.89) | – (7.13) | – (12.9) |
24 | – | Other | SD | – (0.10) | – (1.92) | – (4.01) |
25 | – | Other | NE | – (0.24) | – (14.5) | – (1.16) |
26 | – | Other | SD | – (1.08) | – (17.5) | – (7.12) |
27 | – | Other | SD | – (10.8) | – (24.0) | – (18.4) |
28 | – | None | NE | – (4.24) | – (2.70) | – (19.5) |
29 | – | Other | PD | – (2.10) | – (5.06) | – (10.5) |
30 | – | Other | PR | – (0.45) | – (−3.7) | – (20.6) |
31 | – | Other | PR | – (6.32) | – (8.10) | – (16.0) |
